THYROID DYSFUNCTION AND SUBCLINICAL HYPOTHYROIDISM

by

AS MODIFIABLE DETERMINANTS OF CARDIOVASCULAR RISK IN PATIENTS WITH METABOLIC DISORDERS AND AGE-RELATED CHANGES

Editorial Note

This article was originally published in the journal Zarubezhnaya Meditsina i My in September 2023 (No. 4–2023). The Editorial Board of the International Journal of Interdisciplinary Research approved its republication due to its interdisciplinary relevance to endocrinology, cardiology, metabolic medicine, and clinical gerontology. The text is reproduced with the author’s permission and without substantive changes compared to the original publication.

Abstract

Thyroid hormones exert systemic effects on energy metabolism, lipid homeostasis, vascular tone, and myocardial function. Subclinical hypothyroidism, particularly in older individuals and patients with metabolic disorders, is increasingly regarded as a condition capable of amplifying cardiovascular risk through dyslipidemia, endothelial dysfunction, increased arterial stiffness, and hemodynamic alterations. Diagnostic uncertainty and ongoing debate regarding therapeutic thresholds underscore the need for an integrative approach to thyroid function assessment within cardiometabolic medicine.
This article provides an analytical review of pathophysiological mechanisms linking thyroid dysfunction—primarily subclinical hypothyroidism—to cardiovascular outcomes in patients
with age-associated and metabolic disturbances. Clinical manifestations, diagnostic criteria, risk stratification strategies, and principles of individualized management are discussed.

Keywords:

subclinical hypothyroidism, thyroid hormones, dyslipidemia, endothelial dysfunction, arterial stiffness, cardiovascular risk, metabolic disorders.

Author: Natalia V. Brailova
ORCID: 0009-0002-2155-411X

International Journal of Interdisciplinary Research
Volume 4, Issue 3 (2023)

Peer Reviewer (Acknowledged): Boris Karsakov
ORCID: 0009-0006-4851-6366

DOI: pending

Full Text (PDF)

THYROID-DYSFUNCTION-AND-SUBCLINICAL-HYPOTHYROIDISM

References

  1. Biondi B, Cooper DS. The clinical significance of subclinical thyroid dysfunction. Endocr Rev. 2008;29(1):76–131.
  2. Pearce SHS, Brabant G, Duntas LH, et al. 2013 ETA Guideline: management of subclinical hypothyroidism. Eur Thyroid J. 2013;2(4):215–228.
  3. Razvi S, Weaver JU, Vanderpump MPJ, Pearce SHS. The incidence of ischemic heart disease and mortality in people with subclinical hypothyroidism. J Clin Endocrinol Metab. 2010;95(4):1734–1740.
  4. Rodondi N, den Elzen WPJ, Bauer DC, et al. Subclinical hypothyroidism and the risk of coronary heart disease and mortality. JAMA. 2010;304(12):1365–1374.
  5. Danzi S, Klein I. Thyroid hormone and the cardiovascular system. Med Clin North Am. 2012;96(2):257–268.
  6. Klein I, Danzi S. Thyroid disease and the heart. Circulation. 2007;116(15):1725–1735.
  7. Duntas LH. Thyroid disease and lipids. Thyroid. 2002;12(4):287–293.
  8. Cappola AR, Desai AS, Medici M, et al. Thyroid and cardiovascular disease: research agenda. Circulation. 2019;139(25):2892–2909.
  9. Gussekloo J, van Exel E, de Craen AJM, et al. Thyroid status, disability and cognitive function, and survival in old age. JAMA. 2004;292(21):2591–2599.
  10. Gencer B, Collet TH, Virgini V, et al. Subclinical thyroid dysfunction and cardiovascular outcomes among prospective cohorts. J Clin Endocrinol Metab. 2012;97(7):2253–2262.